Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. | Available online http content 8 6 R1 74 Research article Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden Lars Erik Kristensen Tore Saxne Jan-Ảke Nilsson and Pierre Geborek Open Access Department of Rheumatology Lund University Hospital Kioskgatan 3 SE-221 85 Lund Sweden Corresponding author Lars Erik Kristensen Received 15 Mar 2006 Revisions requested 7 Jun 2006 Revisions received 29 Aug 2006 Accepted 22 Nov 2006 Published 22 Nov 2006 Arthritis Research Therapy 2006 8 R174 doi ar2084 This article is online at http content 8 6 R174 2006 Kristensen et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract The objective of this work is to compare the adherence to therapy of patients receiving etanercept and infliximab during first tumour necrosis factor TNF -blocking treatment course in rheumatoid arthritis. Special emphasis is placed on potential predictors for treatment termination and the impact of concomitant methotrexate MTX or other disease-modifying antirheumatic drugs DMARDs . Patients n 1 161 with active rheumatoid arthritis not responding to at least two DMARDs including MTX starting etanercept or infliximab therapy for the first time were included in a structured clinical follow-up protocol. Information on diagnosis disease duration previous and ongoing DMARDs treatment start and termination as well as cause of withdrawal was prospectively collected during the period of March 1999 through December 2004. Patients were divided into six groups according to TNF-blocking drugs and concomitant DMARDs. .
